Contribute to the growth and development of capacity in Post-Market Drug Safety and Effectiveness (PMDSE) research by: actively engaging trainees, new investigators and researchers and providing supe...
Bernatsky, Sasha R
14 records totalling $7,166,295.00 CAD, from official Government of Canada open data.
Embed this chart
By department
| Canadian Institutes of Health Research | $7,166,295 | 14 records |
Records
Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs
Air pollution and systemic autoimmune rheumatic diseases
The Project Grant program is expected to: • Support a diverse portfolio of health-related research and knowledge translation proposals at any stage, from discovery to application, including commercia...
Hydroxychloroquine in systemic lupus
Pharmacoepidemiology in Multiple Sclerosis (PiMS) Research Group
Canadian Network on Hepatitis C (CanHepC)
Canadian Early Arthritis Cohort (CATCH)
Environment, Epigenetics, and Rheumatic Disease
Cancer risk: Advancing knowledge in systemic rheumatic disease
Post Market Drug Safety and Effectiveness: Ankylosing Spondylitis
Intravitreal bevacizumab for retinal conditions: real-world safety assessment
The initiative is designed to support core health research objectives including investigating critical gaps in climate-health risks and climate-sensitive health outcomes in Canada and building the evi...
Neurodevelopmental Disorders in Children Born to Women with Systemic Lupus Erythematosus